Phase I study of an Epstein-Barr Virus (EBV) in healthy volunteers. The vaccine works by targeting EBV glycoprotein gp350, which is found on the surface of the virus and virus-infected cells. EBV gp350 is also the primary target for neutralizing antibodies found in the blood of people naturally infected with EBV. The study is recruiting 40 healthy adults age 18-29.
https://nihrecord.nih.gov/2022/05/27/ni ... rr-vaccine
It’s been 2.5 years since the study was posted to ClinicalTrials.gov and it’s still in the recruiting status.
https://www.clinicaltrials.gov/ct2/show ... w=2&rank=1
Epstein-Barr Virus Vaccine, Phase I
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1706 Views
-
Last post by Tif
-
- 1 Replies
- 294 Views
-
Last post by Leonard
-
- 2 Replies
- 855 Views
-
Last post by DIM
-
- 0 Replies
- 1349 Views
-
Last post by Tif
-
- 0 Replies
- 1920 Views
-
Last post by Tif
-
- 0 Replies
- 1461 Views
-
Last post by Tif
-
- 1 Replies
- 1116 Views
-
Last post by 1eye
-
- 4 Replies
- 2392 Views
-
Last post by NHE
-
- 0 Replies
- 1669 Views
-
Last post by DIM